Lerisetron
{{Short description|Chemical compound}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462090141
| IUPAC_name = 1-Benzyl-2-piperazin-1-yl-1H-benzimidazole
| image = Lerisetron.svg
| width = 175
| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 143257-98-1
| ATC_prefix = None
| ATC_suffix =
| PubChem = 65997
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 59389
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q36R82SXRG
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 56900
| C=18 | H=20 | N=4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWWDCRQZITYKDV-UHFFFAOYSA-N
| synonyms = F-0930-RS
}}
Lerisetron (code name F-0930-RS) is a drug which acts as an antagonist at the 5-HT3 receptor.{{cite journal | vauthors = Orjales A, Mosquera R, Labeaga L, Rodes R | title = New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation | journal = Journal of Medicinal Chemistry | volume = 40 | issue = 4 | pages = 586–93 | date = February 1997 | pmid = 9046349 | doi = 10.1021/jm960442e }} It is a potent antiemetic{{cite journal | vauthors = Gomez-de-Segura IA, Grande AG, De Miguel E | title = Antiemetic effects of Lerisetron in radiation-induced emesis in the dog | journal = Acta Oncologica | volume = 37 | issue = 7–8 | pages = 759–63 | date = 1998 | pmid = 10050999 | doi = 10.1080/028418698430160 }}{{cite journal | vauthors = Cooper M, Sologuren A, Valiente R, Smith J | title = Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers | journal = Arzneimittel-Forschung | volume = 52 | issue = 9 | pages = 689–94 | date = 2002 | pmid = 12404884 | doi = 10.1055/s-0031-1299952 | s2cid = 24423582 }} and was in clinical trials for the treatment of nausea associated with cancer chemotherapy.{{cite journal | vauthors = Huckle R | title = Lerisetron. FAES | journal = Current Opinion in Investigational Drugs | volume = 4 | issue = 7 | pages = 874–7 | date = July 2003 | pmid = 14619411 }}